IVX-0142(IVX-0142) - _专利_临床

概要

基本信息

药物类型

小分子化药

别名-

靶点-

作用机制-

治疗领域

免疫系统疾病呼吸系统疾病

在研适应症-

非在研适应症

过敏性哮喘哮喘

原研机构

Teva Pharmaceutical Industries Ltd.

在研机构-

非在研机构

Teva Pharmaceutical Industries Ltd.Teva Branded Pharmaceutical Products R&D, Inc.

最高研发阶段无进展临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

1

项与 IVX-0142 相关的临床试验

NCT00232999

/ Completed临床2期

Efficacy/Safety Study of Nebulized IVX-0142, a Novel Antiallergic Drug, in Mild Allergic Asthma

This study is designed to evaluate the effectiveness of nebulized IVX-0142, a novel anti-allergic drug, to inhibit allergen-induced airway narrowing in patients with allergic asthma and the related increased sensitivity of the airways to other substances, as well as to investigate a possible anti-inflammatory effect of the drug in the airways.

开始日期2005-10-01

申办/合作机构

Teva Branded Pharmaceutical Products R&D, Inc.

[+1]

100 项与 IVX-0142 相关的临床结果

登录后查看更多信息

100 项与 IVX-0142 相关的转化医学

登录后查看更多信息

100 项与 IVX-0142 相关的专利（医药）

登录后查看更多信息

1

项与 IVX-0142 相关的文献（医药）

2008-12-01·Methods and findings in experimental and clinical pharmacology

Gateways to clinical trials. December 2008.

作者: Tomillero, A ; Moral, M A

Gateways to Clinical Trials is a guide to the most recent clinical trials in current literature and congresses. The data in the following tables have been retrieved from the Clinical Trials Knowledge Area of Prous Science Integrity, the drug discovery and development portal, http://integrity.prous.com. This issue focuses on the following selection of drugs: AAV1/SERCA2a; Abatacept, ABT-263, Adalimumab, Aflibercept, Afobazole, Aliskiren fumarate, Anakinra, Atazanavir/ritonavir, Aviscumine, Axitinib, Azacitidine; Bevacizumab, Biphasic insulin aspart, Bortezomib, Briobacept; Carmoterol hydrochloride, CCX-282, Ceftobiprole medocaril, Certolizumab pegol, Cetuximab; Darifenacin hydrobromide, Dasatinib, Denosumab, Doripenem, Duloxetine hydrochloride; E-7080, Epratuzumab, Erlotinib hydrochloride, Everolimus, Exenatide, Ezetimibe/simvastatin; Gefitinib, Golimumab; gamma-Hydroxybutyrate sodium; Imatinib mesylate, Insulin detemir, Insulin glulisine, IVX-0142; Laquinimod sodium, Linezolid, Lopinavir/ritonavir; Ocrelizumab, Omalizumab; Parecoxib sodium, Pemetrexed disodium, Pregabalin; Rosuvastatin calcium, Rotigotine; Sorafenib, Sugammadex sodium; Tapentadol hydrochloride, Tenofovir disoproxil fumarate/emtricitabine, Tocilizumab; Ularitide, Ustekinumab; Valsartan/amlodipine besylate, Varenicline tartrate, Vatalanib succinate, Vildagliptin, Vorinostat.

100 项与 IVX-0142 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
过敏性哮喘	临床2期	加拿大	Teva Branded Pharmaceutical Products R&D, Inc.	2005-10-01
哮喘	临床2期	加拿大	Teva Pharmaceutical Industries Ltd.	2005-10-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT00232999 (Pubmed \| Allergy)	临床2期	哮喘	19	IVX-0142 (80 mg)	築憲鏇築製鬱觸淵醖遞(構憲窪獵膚襯鬱顧積繭) = a trend in the attenuation of allergen-induced increase in the absolute sputum cell counts was also observed 鏇糧餘簾構艱顧鏇鹽膚 (願繭積選選鬱範艱選繭 )	-	2008-09-01
				Placebo